click below
click below
Normal Size Small Size show me how
Hormone Tx
Oncology Exam #3
| Drug Name | Drug Class | MOA | Side effects | Drug interactions |
|---|---|---|---|---|
| Goserelin | GnRH agonists | Continuous exposure to GnRH agonist will suppress LH/FSH pituitary secretion which then reduces testosterone production. (negative feedback) | ||
| Leuprolide | GnRH agonists | Continuous exposure to GnRH agonist will suppress LH/FSH pituitary secretion which then reduces testosterone production. (negative feedback) | ||
| Triptorelin | GnRH agonists | Continuous exposure to GnRH agonist will suppress LH/FSH pituitary secretion which then reduces testosterone production. (negative feedback) | ||
| Relugolix | GnRH antagonist | |||
| Degarelix | GnRH antagonist | |||
| Finasteride | 5α-Reductase Inhibitors | |||
| Dutasteride | 5α-Reductase Inhibitors | |||
| Abiraterone acetate | P450c17 inhibitors | |||
| Anastrozole | Aromatase Inhibitors | |||
| Letrozole | Aromatase Inhibitors | |||
| Exemestane | Aromatase Inhibitors | |||
| Tamoxifen | Selective Estrogen Receptor Modulators (SERMs) | |||
| Raloxifene | Selective Estrogen Receptor Modulators (SERMs) | |||
| Fulvestrant | Selective Estrogen-Receptor Downregulators (SERDs) | |||
| Bicalutamide | Selective Estrogen-Receptor Downregulators (SERDs) | |||
| Flutamide | Selective Estrogen-Receptor Downregulators (SERDs) | |||
| Nilutamide | Selective Estrogen-Receptor Downregulators (SERDs) | |||
| Enzalutamide | Selective Estrogen-Receptor Downregulators (SERDs) | |||
| Apalutamide | Selective Estrogen-Receptor Downregulators (SERDs) | |||
| Darolutamide | Selective Estrogen-Receptor Downregulators (SERDs) | |||
| Inavolisib | PI3K inhibitor | Inhibitor of phosphatidylinositol 3-kinase (PI3K) which decreases cell proliferation and induces apoptosis | ||
| Zolendroic Acid | Biphosphonates | Binds to hydroxyapatite in bone which inhibits osteoclast-mediated bone resorption | ||
| Denosumab | RANK ligand inhibitor | Binds to RANKL, blocking RANKL binding to RANK on the surface of osteoclast precursor cells; inhibits osteoclastogenesis | ||
| Radium-233 | Targeted radiation therapy | Radioactive agent that emits alpha particles --> break DNA in adjacent cells --> kill them. | ||
| Sipuleucel-T | Autologous cellular immunotherapy | Induces an immune cell response against prostate acidic phosphatase (PAP), which is expressed in most prostate cancers | ||